Donaldson acquires Isolere Bio

By Rachel Arthur

- Last updated on GMT


Related tags Chromatography Filtration purification

Donaldson Company will acquire Isolere Bio: an early-stage biotech that develops novel and proprietary ‘IsoTag’ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Aimed initially at the purification of viral vectors used for cell and gene therapies, IsoTag reagents are designed to ‘substantially improve product quality and purity with faster timelines compared to competing solutions, enabling accelerated and more affordable delivery of life-changing therapies to patients globally’.

Founded in 2017 by Kelli Luginbuhl, Ph.D, Professor Ashutosh Chilkoti, and Joe McMahon, Isolere is headquartered in Durham, North Carolina.

Raft of acquisitions

Donaldson Company - a provider of filtration products and solutions for a range of industries and markets headquartered in Minneapolis - says the acquisition will help it tap into growth areas in the pharmaceutical industry.

It follows the 2021 acquisition of Italian company Solaris​, which designs and manufactures bioprocessing equipment including bioreactors, fermenters and tangential flow filtration systems for use in food and beverage, biotech and other life science markets.

And in 2022, it acquired US biotech Purilogics, which leverages a novel technology platform for the development of membrane chromatography products (its purification tools are for a wide range of biologics, including mRNA, plasmid DNA, viral particles, monoclonal antibodies and proteins).

“With the integral addition of Isolere to our Life Sciences portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs,”​ said Tod Carpenter, chairman, president and chief executive officer of Donaldson. “We look forward to accelerating Isolere’s growth trajectory through sales synergies from our recent acquisitions of Solaris Biotechnology and Purilogics and through the strength of our balance sheet.”

“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere. “Our technology, complemented by Donaldson’s filtration excellence, is part of a larger vision to bring end-to-end solutions to the life sciences industry.”

Once commercialized, revenue from Isolere will be reported within the Donaldson Life Sciences segment.

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us